Hikma Pharmaceuticals Plc Annual Financial Report and Notice of AGM
22 Marzo 2024 - 3:21AM
RNS Regulatory News
RNS Number : 9694H
Hikma Pharmaceuticals Plc
22 March 2024
Hikma Pharmaceuticals PLC
2023 Annual Report and
Accounts and Notice of 2024 Annual General
Meeting
LONDON, 22 March 2024:
Hikma Pharmaceuticals PLC (the "Company") announces that, the Annual
Report and Accounts for the year ended 31 December 2023 (the
"Annual Report") and the
Notice of the 2024 Annual General Meeting (the "Notice of AGM") are today being made
available to shareholders.
The Annual Report and Notice of AGM
can be viewed or downloaded from the Company's website at
www.hikma.com/investors/2023-annual-report/.
In accordance with Listing Rule
9.6.1 copies of the Annual Report and Notice of AGM have been
submitted to the National Storage Mechanism and will shortly be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
ENDS -
Enquiries
Hikma Pharmaceuticals PLC
Helen
Middlemist
+44 20 7399 2760
Group Company Secretary
22 March 2024
About Hikma
Hikma helps put better health within
reach every day for millions of people around the world. For more
than 45 years, we've been creating high-quality medicines and
making them accessible to the people who need them. Headquartered
in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe,
and we use our unique insight and expertise to transform
cutting-edge science into innovative solutions that transform
people's lives. We're committed to our customers, and the people
they care for, and by thinking creatively and acting practically,
we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,100 colleagues are helping to
shape a healthier world that enriches all our communities. We are a
leading licensing partner, and through our venture capital arm, are
helping bring innovative health technologies to people around the
world. For more information, please visit:
www.hikma.com.
Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated
BBB-/stable S&P, BBB-/positive Fitch)
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
ACSUUUKRSRUOURR
Hikma Pharmaceuticals (LSE:HIK)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Hikma Pharmaceuticals (LSE:HIK)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
